{'fraction_non_alphanumeric': 0.018448023426061493, 'fraction_numerical': 0.0008784773060029283, 'mean_word_length': 5.711198428290766, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Importance of Participant Tracking When Conducting Clinical Pharmacology Drug Trials

The American College of Clinical Pharmacology (ACCP) strongly recommends the use of research participant databases, registries, or independent monitoring organizations to oversee the recruitment and enrollment of participants in clinical pharmacology trials. All clinical research trials involve a level of risk. It is the ethical responsibility of sponsors, ethical review boards, and researchers for these trials to ensure that this risk is minimized, and participant safety maximized, to the extent possible based on the available data at that time. Trial risk mitigation is primarily managed through trial design, conduct, and independent ethical review. An important aspect of trial conduct is participant recruitment and enrollment. It is therefore paramount that those participating in the trial fully meet the inclusion and exclusion criteria set forth in the protocol and be truthful regarding previous trial experience during the screening phase of the trial. Clinical pharmacology trials, also termed phase I development trials, play a pivotal role in the initial safety investigation, regulatory approval, and continued lifecycle management of all pharmaceutical therapies. These trials rely on the ability to recruit and enroll participants of different ages, races, ethnicities, sex, weight, and health status to best characterize the pharmacokinetics, pharmacodynamics, and initial tolerability of medicinal products. Among the various types of trials conducted, phase I trials typically include those that assess the administration of single and multiple doses of a novel compound for the first time in humans. They may also include, but are not limited to, assessing the effects of renal and/or hepatic impairment, differences in drug absorption, cardiac function, concomitant drug interactions, and different formulations. These studies play a critical role in the development of safe and effective new therapies. As such, the demand for these trials and the competitive nature of medical research create an environment of consistent demand for clinic resources and healthy volunteers, rapid timelines, and the potential for high financial gain for those involved. While some individuals participate in clinical trials for altruistic or socially based reasons, compensation for time and travel motivates the participation of many others, thus creating an environment where participants may rely on this compensation as either supplemental to or as their sole or main source of income. These “occupational” or “professional” research individuals will seek out and enroll in numerous types of trials throughout a calendar year, at times in quick succession, and may even attempt to participate in more than 1 trial simultaneously.1 Current literature has indicated that approximately one-third of those participating in clinical pharmacology studies fall into this “occupational” category.1 Unfortunately, some participants take an indifferent attitude toward the risks inherent in participating in multiple trials over short periods of time or enrolling in trials sequentially, even though they are well informed and repeatedly warned of the risks by the researchers conducting these trials. Concerningly, to maximize their clinical trial compensation over time, participants have been known to deceive trial